AdvanSix Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASIX research report →
Range $19 – $25
Price Chart
About the company
AdvanSix Inc. operates as a global manufacturer and supplier of polymer resins, serving markets across the United States and internationally. A key offering is Nylon 6, a versatile synthetic polymer resin utilized in the production of fibers, filaments, specialized plastics, and films.
- CEO
- Erin N. Kane
- IPO
- 2016
- Employees
- 1,410
- HQ
- Parsippany, NJ, US
Get TickerSpark's AI analysis on ASIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $347.33M
- P/E
- -16.24
- Fwd P/E
- 8.60
- PEG
- 0.13
- P/S
- 0.23
- P/B
- 0.47
- EV/EBITDA
- 13.78
- Div Yield
- 4.69%
- Gross Margin
- 4.55%
- Op Margin
- -1.74%
- Net Margin
- -1.40%
- ROE
- -2.84%
- ROIC
- -1.69%
Latest fiscal year · YoY change
- Revenue
- $1.52B+0.3%
- Gross Profit
- $173.64M+13.5%
- Op Income
- $67.52M
- Net Income
- $49.29M+11.6%
- EPS
- $1.83+10.9%
- OCF Growth
- -9.3%
- FCF Growth
- +279.5%
- 52W High
- $26.73
- 52W Low
- $12.67
- 50D MA
- $15.92
- 200D MA
- $19.42
- Beta
- 1.26
- RSI (14)
- 29
- Avg Volume
- 281.93K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AdvanSix said third-quarter sales grew 15% year over year and cash flow improved, but EBITDA fell as higher raw-material and fixed-cost absorption pressures offset strong pricing.· November 4, 2026
- Sales rose 15% year over year to $431 million, helped by pricing increases across all product lines.
- Adjusted EBITDA was $15 million and adjusted EPS was a $0.24 loss, both down from last year on higher raw-material costs and lower production output.
- Cash generation improved: operating cash flow was $48 million and free cash flow was $30 million in the quarter.
- Management kept emphasizing commercial execution, working-capital discipline, and a multi-year $30 million fixed-cost reduction program.
- Project CENTURY received proposed $47 million USDA FIELDS funding, and management said 2027 capex should start around $80 million before incremental discretionary spend.
Third-quarter sales increased 15% year over year to $431 million. Adjusted EBITDA was $15 million, down $10 million from last year, and adjusted earnings per share was a loss of $0.24, down $0.32 year over year. Gross margin was not stated on the call. Pricing rose 17% overall, partially offset by a 2% volume decline; raw-material pass-through pricing was up 10% and market-based pricing improved 7%. Operating cash flow was $48 million, up $21 million year over year, capex was $18 million, and free cash flow was $30 million for the quarter. Management said full-year 2026 effective tax rate should be about 20%. For the fourth quarter, management expects price-over-raws to be a headwind year over year, while working-capital tailwinds should continue and ammonium sulfate pre-buy activity should support cash flow. Full-year 2026 capex is now expected to be about $90 million, including $75 million of base capital and $15 million of high-return growth investments.
Erin Kane framed the quarter as evidence that AdvanSix’s integrated model can offset inflation through pricing, even though lower production and fixed-cost absorption pressured earnings. She stressed controllable levers: commercial execution, operational excellence, disciplined capital deployment, and a continued focus on cash conversion. Her tone was constructive but guarded, with optimism tied to reliability improvements, the fixed-cost reduction program, and strategic growth projects like SUSTAIN, Project CENTURY, and potential DEF investment.
Patrick Day emphasized that pricing gains were the main offset to higher raw materials, with 17% favorable pricing versus a 2% volume decline. He said raw-material costs were the biggest headwind at $65 million, while SG&A was a roughly $3 million benefit from cost discipline and the absence of prior-year ERP spending; all other items were an $8 million headwind from reduced production output. He also highlighted improved cash performance, with operating cash flow of $48 million, $30 million of free cash flow in the quarter, expected full-year 2026 capex of about $90 million, and a 2026 tax rate of about 20%. In Q&A he said the company sees a path to break-even free cash flow in the calendar year, excluding the expected $18 million 45Q refund.
Analysts focused on Project CENTURY timing, financing, and how additional ammonia capacity would be allocated. Management said 2027 spending on Project CENTURY would be modest, with peak spend likely in 2029 to 2031, and that the 2027 capex starting point is around $80 million before additional discretionary projects. On pre-buy activity and free cash flow, Patrick Day said Q4 pre-buy should be positive and could help support higher cash generation, while Erin Kane and Day also discussed the expected $18 million 45Q refund, which may slip into 2027 for procedural reasons. Questions on Plant Nutrients and Nylon centered on supply/demand and operating rates; management said sulfur normalization should benefit margins, while caprolactam operations remain roughly 8% to 10% below healthier-market levels.
The quarter showed that AdvanSix can raise prices enough to nearly offset higher raw materials, while still improving cash flow. Management pointed to tighter ammonium sulfate supply, stable end demand in nylon and chemical intermediates, and strategic projects that could add capacity, improve reliability, and strengthen returns, including Project CENTURY with a proposed $47 million grant.
Earnings were pressured by a $65 million raw-material headwind, lower production output, and unfavorable fixed-cost absorption, and management expects price-over-raws to remain a fourth-quarter headwind. Plant Nutrients still faces elevated sulfur costs and seasonal pressure, caprolactam demand remains soft in building and construction, and management acknowledged export markets are fundamentally challenged. There is also execution and timing risk around grant approvals, Project CENTURY ramp timing, potential 45Q refund timing, and a still-evolving 2027 capital plan.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.8%
- Shares Outstanding
- 27.01M
- Float Shares
- 24.51M
of shares held by institutions
258 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ASIX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.64M | ▲ 194.85K |
| Vanguard Group Inc | 1.71M | ▼ 283.30K |
| American Century Companies Inc | 1.52M | ▲ 154.26K |
| Dimensional Fund Advisors LP | 1.43M | ▲ 25.51K |
| Vanguard Capital Management LLC | 1.14M | ▼ 12.62K |
| Castleknight Management LP | 978.09K | ▼ 612.23K |
| Aegis Financial Corp | 959.53K | ▼ 250.10K |
| Alliancebernstein L.P. | 876.51K | ▲ 12.62K |
| Geode Capital Management, LLC | 664.87K | ▼ 27.65K |
| Solas Capital Management, LLC | 657.32K | ▲ 86.00K |
| Fmr LLC | 657.21K | ▼ 1.11K |
| State Street Corp | 588.48K | ▲ 824 |
Held by 183 ETFs
Biggest fund positions in ASIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Williams Patrick | other | 785 |
| Jun 30, 26 | Williams Patrick | other | 660 |
| Jun 22, 26 | Bird Jeffrey J. | other | 6,207 |
| Jun 22, 26 | Karran Todd D. | other | 6,207 |
| Jun 22, 26 | Lovett Gena C | other | 6,207 |
| Jun 22, 26 | NEWMAN DONALD P | other | 6,207 |
| Jun 22, 26 | O'Brien Dana C. | other | 6,207 |
| Jun 22, 26 | Roberts Daryl | other | 6,207 |
| Jun 22, 26 | Spurlin Sharon | other | 6,207 |
| Jun 22, 26 | Williams Patrick | other | 6,207 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASIX coverage
Recent articles, reports, and earnings notes.
No research on ASIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASIX report →What AdvanSix (ASIX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
AdvanSix Inc. (ASIX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
AdvanSix Announces Third Quarter 2026 Financial Results
businesswire.com · Nov 4
AdvanSix Secures $47.4M USDA Grant to Expand Ammonia Capacity
zacks.com · Nov 3
AdvanSix Selected for $47.4 Million Grant to Expand American Manufacturing
businesswire.com · Oct 29
5N Plus (OTCMKTS:FPLSF) and AdvanSix (NYSE:ASIX) Head to Head Review
defenseworld.net · Oct 15
AdvanSix to Release Third Quarter Financial Results and Hold Investor Conference Call on November 4
businesswire.com · Oct 6
AdvanSix: Challenges Persist, My Downgrade Was Correct
seekingalpha.com · Aug 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.